Open access
Open access
Powered by Google Translator Translator

Radiation Oncology

Phase 2 RCT | Adding stereotactic body radiotherapy to immune checkpoint inhibitors fails to improve outcomes in solid tumor patients

9 Aug, 2023 | 15:28h | UTC

Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

See also: Visual Abstract

Commentary: Addition of SBRT to Immunotherapy in Advanced Solid Tumors – The ASCO Post

 


RCT | Upfront radiosurgery reduces tumor volume vs. a wait-and-scan approach in small- to medium-sized vestibular schwannoma

7 Aug, 2023 | 14:40h | UTC

Upfront Radiosurgery vs a Wait-and-Scan Approach for Small- or Medium-Sized Vestibular Schwannoma: The V-REX Randomized Clinical Trial – JAMA (free for a limited period)

See also: Visual Abstract

 

Commentary on Twitter

 


RCT | Dysphagia-optimized intensity-modulated radiotherapy better preserves swallowing function in pharyngeal cancer patients

25 Jul, 2023 | 13:52h | UTC

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial – The Lancet Oncology

Commentaries:

Dysphagia-Optimized vs Standard IMRT in Newly Diagnosed Patients With Head and Neck Cancer – The ASCO Post

Radiation approach improves swallowing in head, neck cancer – MDedge

 

Commentary on Twitter

 


Phase 2 Trial | The addition of immunotherapy to stereotactic ablative radiotherapy may enhance EFS in early-stage NSCLC

25 Jul, 2023 | 13:36h | UTC

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial – The Lancet (link to abstract – $ for full-text)

 


Systematic Review | Post-mastectomy RT likely lowers recurrence and improves survival in early breast cancer with 1-3 positive nodes

25 Jul, 2023 | 13:34h | UTC

Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes – Cochrane Library

Summary: Is X-ray treatment (radiotherapy) after removal of breast tissue (mastectomy) better than no X-ray treatment in women diagnosed with breast cancer that has spread to one to three armpit lymph nodes? – Cochrane Library

 


RCT | Brachytherapy alone sufficient for intermediate-risk prostate cancer, no FFP improvement with additional EBRT

7 Jul, 2023 | 16:06h | UTC

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

News Release: Addition of EBRT to brachytherapy did not improve outcomes for men with intermediate-risk prostate cancer, brachytherapy alone remains standard of care – NRG Oncology

 


ESTRO-ACROP guideline | Recommendations on implementation of breath-hold techniques in radiotherapy

22 Jun, 2023 | 14:51h | UTC

ESTRO-ACROP guideline: Recommendations on implementation of breath-hold techniques in radiotherapy – Radiotherapy and Oncology

 


RCT | Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer

15 Jun, 2023 | 15:04h | UTC

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial – The Lancet

 


M-A | Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy

5 Jun, 2023 | 13:29h | UTC

Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis – The Lancet Oncology (free for a limited period)

 

Commentary from the author on Twitter

 


MASCC Guidelines for the prevention and management of acute radiation dermatitis | Part 1 – Systematic review

29 May, 2023 | 10:53h | UTC

MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1) systematic review – eClinicalMedicine

Related:

RCT | Bacterial decolonization for prevention of radiation dermatitis

RCT | Mepitel film for the prevention of acute radiation dermatitis in breast cancer.

 


RCT | Bacterial decolonization for prevention of radiation dermatitis

8 May, 2023 | 12:46h | UTC

Bacterial Decolonization for Prevention of Radiation Dermatitis: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)

News Release: A Simple Antibacterial Treatment Solves a Severe Skin Problem Caused by Radiation Therapy – Montefiore Einstein Cancer Center

 

Commentary on Twitter

 


ASTRO/ESTRO Guideline | Treatment of oligometastatic non-small cell lung cancer

4 May, 2023 | 13:44h | UTC

Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline – Practical Radiation Oncology

News Release: ASTRO and ESTRO issue clinical guideline on local therapy for oligometastatic lung cancer – American Society for Radiation Oncology (ASTRO)

Commentary: ASTRO and ESTRO Issue New Clinical Guidelines on Local Therapy for Patients With Oligometastatic NSCLC – The ASCO Post

 

Commentary on Twitter

 


AUA/SUO Guideline | Updates to Advanced Prostate Cancer

2 May, 2023 | 13:46h | UTC

Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023) – The Journal of Urology

 


Consensus Paper | Management of pathological thoracolumbar vertebral fractures in patients with multiple myeloma

25 Apr, 2023 | 14:11h | UTC

Management of Pathological Thoracolumbar Vertebral Fractures in Patients With Multiple Myeloma: Multidisciplinary Recommendations – Global Spine Journal

 


RCT | Stereotactic radiosurgery vs. conventional radiotherapy for localized vertebral metastases of the spine

24 Apr, 2023 | 13:37h | UTC

Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine: Phase 3 Results of NRG Oncology/RTOG 0631 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Audio interview: Radiosurgery of Spine Metastasis—NRG/RTOG 0631 RCT Final Results – JAMA

 

Commentary on Twitter

 


RCT | MRI–guided vs CT–guided stereotactic body radiotherapy for prostate cancer

18 Apr, 2023 | 12:52h | UTC

Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial – JAMA Oncology

News Release: MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer – University of California – Los Angeles Health Sciences

 


Phase 2 RCT | Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer

10 Apr, 2023 | 13:41h | UTC

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 


RCT | Effects of Docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation

29 Mar, 2023 | 13:05h | UTC

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation – Journal of Clinical Oncology (link to abstract – $ for full-text)

Editorial: Good Radiosensitizer Hunting – Journal of Clinical Oncology

Commentaries:

Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC – OncLive

Docetaxel as a Radiosensitizer in Cisplatin-Ineligible Patients With Locally Advanced Head and Neck Cancer – The ASCO Post

 


RCT | Hyperfractionation vs. standard fractionation in IMRT for patients with locally advanced recurrent nasopharyngeal carcinoma

22 Mar, 2023 | 13:12h | UTC

Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Hyperfractionated vs Standard-Fractionation IMRT in Locally Advanced, Recurrent Nasopharyngeal Carcinoma – The ASCO Post

 


RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer

15 Mar, 2023 | 15:24h | UTC

Summary: The article reports on a study that evaluated patient-reported outcomes of 1,643 participants in the ProtecT trial over a period of 7 to 12 years to assess the long-term functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring for localized prostate cancer detected by PSA screening.

The study found that generic quality-of-life scores were similar among the randomized groups over 7 to 12 years. However, although the prostatectomy group had a lower incidence of nocturia, they showed a higher incidence of urinary incontinence and sexual dysfunction compared to the radiotherapy and active monitoring groups. The radiotherapy group had a higher incidence of fecal leakage compared to the other groups.

The study provides evidence that helps patients and their clinicians assess the trade-offs between treatment harms and benefits and make better-informed treatment decisions.

Article: Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment – NEJM Evidence

Original Study: RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes

 


Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer

14 Mar, 2023 | 13:21h | UTC

Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer – Cochrane Library

Summary: Dose-escalated radiotherapy for curative treatment in men with clinically localized prostate cancer – Cochrane Library

 


RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes

13 Mar, 2023 | 15:12h | UTC

Summary: The study followed 1643 men diagnosed with localized prostate cancer (diagnosed by screening with PSA) in the United Kingdom between 1999 and 2009 who were randomly assigned to receive active monitoring, prostatectomy, or radiotherapy.

After a median follow-up of 15 years, the study found that while prostatectomy and radiotherapy decreased metastasis, local progression, and the need for long-term androgen deprivation therapy, death from prostate cancer was low regardless of the treatment assigned, with 17 deaths (3.1%) in the active-monitoring group, 12 deaths (2.2%) in the prostatectomy group, and 16 (2.9%) deaths in the radiotherapy group (P=0.53). Additionally, the study found that overall deaths were similar between the groups.

The authors suggest that the choice of therapy for localized prostate cancer involves weighing the benefits and harms associated with each treatment option.

Article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Delaying treatment for localised prostate cancer does not increase mortality risk, trial shows – University of Bristol

 

Commentary on Twitter

 


RCT | Breast-conserving surgery without irradiation may be an option for older patients with early breast cancer

17 Feb, 2023 | 13:25h | UTC

Summary: The article reports a phase 3 randomized trial that investigated the efficacy of omitting irradiation after breast-conserving surgery in women aged 65 years or older with hormone receptor-positive, node-negative, T1 or T2 primary breast cancer, and tumors ≤3 cm in the largest dimension, who received adjuvant endocrine therapy. A total of 1326 women were enrolled, with 658 receiving whole-breast irradiation and 668 receiving no irradiation. The results showed that the omission of radiotherapy led to an increased incidence of local breast cancer recurrence but had no negative effect on distant recurrence as the first event or overall survival. The study suggests that omission of radiotherapy could be a viable treatment option for older women with low-risk, hormone receptor–positive early breast cancer who receive adjuvant endocrine therapy.*

Article: Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

For many older breast cancer patients, study finds radiation doesn’t affect survival – STAT

Do Older Patients Need Radiation Rx After Breast Cancer Surgery? – HealthDay

 

*Note: This summary was created through the collaboration of a medical editor and ChatGPT.

 


Development and validation of a genomic profile for the omission of local adjuvant radiation in breast cancer

16 Feb, 2023 | 14:39h | UTC

Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer – Journal of Clinical Oncology

 


Development of a machine learning model for sonographic assessment of gestational age

14 Feb, 2023 | 10:30h | UTC

Development of a Machine Learning Model for Sonographic Assessment of Gestational Age – JAMA Network Open

Commentary: AI Models Have Higher Accuracy for Estimating Gestational Age – HealthDay

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.